<?xml version='1.0' encoding='UTF-8'?>

      <!-- iXBRL document created with: Toppan Merrill Bridge iXBRL 9.6.7401.38943 -->
      <!-- Based on: iXBRL 1.1 -->
      <!-- Created on: 5/15/2020 8:04:21 PM -->
      <!-- iXBRL Library version: 1.0.7401.38955 -->
      <!-- iXBRL Service Job ID: 060ff61e-b681-4355-85e5-ebfa498e5a6f -->

  <html xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns="http://www.w3.org/1999/xhtml" xmlns:edit="http://www.editasmedicine.com/20200515" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrli="http://www.xbrl.org/2003/instance"><head><meta http-equiv="content-type" content="text/html" /><title></title></head><body><div style="margin-top:30pt;"></div><div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric contextRef="Duration_5_15_2020_To_5_15_2020_JKlsoBudLEG9zjmLPSA4Ow" name="dei:EntityCentralIndexKey" id="Tc_PGcDyYl0XUm5vAszdqxcKg_2_1">0001650664</ix:nonNumeric><ix:nonNumeric contextRef="Duration_5_15_2020_To_5_15_2020_JKlsoBudLEG9zjmLPSA4Ow" name="dei:AmendmentFlag" id="Tc_HX22MgMDIUKd1UQfguPrTg_3_1">false</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:href="edit-20200515.xsd" xlink:type="simple"></link:schemaRef></ix:references><ix:resources><xbrli:context id="Duration_5_15_2020_To_5_15_2020_JKlsoBudLEG9zjmLPSA4Ow"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-15</xbrli:startDate><xbrli:endDate>2020-05-15</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;min-height:15.52pt;"><a id="_6bb3e728_7f0a_469a_8fbb_840da447ef8c"></a><p style="font-family:'Times New Roman';font-size:12pt;padding-bottom:1pt;padding-top:1pt;text-align:center;border-bottom:1.0pt solid #000000;border-top:3.0pt solid #000000;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><b style="font-size:18pt;font-weight:bold;">UNITED STATES<br />SECURITIES AND EXCHANGE COMMISSION</b></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">WASHINGTON, D.C. 20549</b></p><div style="font-family:'Times New Roman';font-size:13.5pt;margin-bottom:6pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:38.36%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman';font-size:18pt;font-weight:bold;text-align:center;margin:0pt 0pt 3pt 0pt;">FORM&#160;<ix:nonNumeric contextRef="Duration_5_15_2020_To_5_15_2020_JKlsoBudLEG9zjmLPSA4Ow" name="dei:DocumentType" id="Narr_tOuBe7Po_UulwbtvYd364g">8-K</ix:nonNumeric></p><div style="font-family:'Times New Roman';font-size:13.5pt;margin-bottom:9pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:38.36%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">CURRENT REPORT<br />Pursuant to Section&#160;13 or 15(d)<br />of The Securities Exchange Act of 1934</b></p><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><span style="font-size:10pt;white-space:pre-wrap;">Date of Report (Date of earliest event reported):  </span><ix:nonNumeric contextRef="Duration_5_15_2020_To_5_15_2020_JKlsoBudLEG9zjmLPSA4Ow" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="Narr_ftI-YgUDFU2eO5XdhOl90g"><span style="font-size:10pt;">May 15, 2020</span></ix:nonNumeric></p><div style="font-family:'Times New Roman';font-size:13.5pt;margin-bottom:6pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:38.36%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman';font-size:18pt;font-weight:bold;text-align:center;margin:0pt 0pt 3pt 0pt;"><ix:nonNumeric contextRef="Duration_5_15_2020_To_5_15_2020_JKlsoBudLEG9zjmLPSA4Ow" name="dei:EntityRegistrantName" id="Narr_oYoUNf4No0a-WZa2MlvYhQ">Editas Medicine, Inc.</ix:nonNumeric></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">(Exact Name of Registrant as Specified in its Charter)</p><div style="font-family:'Times New Roman';font-size:13.5pt;margin-bottom:6pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:38.36%;border:none;margin:0 auto;"><a id="_3adfa712_def6_4d30_8ee6_bcc325048289"></a><a id="Tc__B_MHccpLUiOmeZ7YBew0Q_2_0"></a><a id="Tc_BON6HRm1y06L8dCB9z4aog_2_2"></a><a id="Tc_pZf0BWlF8kKunBZAN7QoOw_2_4"></a></div></div><table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 12pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 12pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_5_15_2020_To_5_15_2020_JKlsoBudLEG9zjmLPSA4Ow" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="Tc_X5uualFnzEKOCVjNzU8NqA_1_0"><b style="font-size:10pt;font-weight:bold;">Delaware</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_5_15_2020_To_5_15_2020_JKlsoBudLEG9zjmLPSA4Ow" name="dei:EntityFileNumber" id="Tc_yssiStBleESOJH1ItaC1nQ_1_2"><b style="font-size:10pt;font-weight:bold;">001-37687</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_5_15_2020_To_5_15_2020_JKlsoBudLEG9zjmLPSA4Ow" name="dei:EntityTaxIdentificationNumber" id="Tc_id_D5l0qUU6aaSoNbIn1Fw_1_4"><b style="font-size:10pt;font-weight:bold;">46-4097528</b></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:top;width:32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;">(State or Other Jurisdiction of Incorporation)</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;">(Commission File Number)</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;">(IRS Employer Identification No.)</p></td></tr></table><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_96b041bf_580e_4f57_a6fd_8289c17b8595"></a><a id="Tc_S5JB8Bx1ZkybRVusT8FFSQ_1_0"></a><a id="Tc__FbHMXDC9k--PhnOoNXokQ_2_0"></a><a id="Tc_zn7dcx7veUKtkS0GyIVHAA_2_2"></a><table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 12pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_5_15_2020_To_5_15_2020_JKlsoBudLEG9zjmLPSA4Ow" name="dei:EntityAddressAddressLine1" id="Narr_gu4RpHEKfE6SpCEFHqwvfA"><b style="font-size:10pt;font-weight:bold;">11 Hurley Street</b></ix:nonNumeric><b style="font-size:10pt;font-weight:bold;"><br /></b><ix:nonNumeric contextRef="Duration_5_15_2020_To_5_15_2020_JKlsoBudLEG9zjmLPSA4Ow" name="dei:EntityAddressCityOrTown" id="Narr_6S5fpzbNUkG5irx_burKfQ"><b style="font-size:10pt;font-weight:bold;">Cambridge</b></ix:nonNumeric><b style="font-size:10pt;font-weight:bold;">, </b><ix:nonNumeric contextRef="Duration_5_15_2020_To_5_15_2020_JKlsoBudLEG9zjmLPSA4Ow" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince" id="Narr_-uj_M6YbUU6evy2CEjvtLg"><b style="font-size:10pt;font-weight:bold;">Massachusetts</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_5_15_2020_To_5_15_2020_JKlsoBudLEG9zjmLPSA4Ow" name="dei:EntityAddressPostalZipCode" id="Tc_cPCTBxrnGkaEa2ktB6k8ZA_1_2"><b style="font-size:10pt;font-weight:bold;">02141</b></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;">(Address of Principal Executive Offices)</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;">(Zip Code)</p></td></tr></table><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><span style="font-size:10pt;">Registrant&#8217;s telephone number, including area code:&#160;</span><b style="font-size:10pt;font-weight:bold;">(</b><ix:nonNumeric contextRef="Duration_5_15_2020_To_5_15_2020_JKlsoBudLEG9zjmLPSA4Ow" name="dei:CityAreaCode" id="Narr_0wnWwttC8UujftRwrkLPAQ"><b style="font-size:10pt;font-weight:bold;">617</b></ix:nonNumeric><b style="font-size:10pt;font-weight:bold;">)&#160;</b><ix:nonNumeric contextRef="Duration_5_15_2020_To_5_15_2020_JKlsoBudLEG9zjmLPSA4Ow" name="dei:LocalPhoneNumber" id="Narr__mN_qAvY2ESZ1CC95dUDnw"><b style="font-size:10pt;font-weight:bold;">401-9000</b></ix:nonNumeric></p><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;">(Former Name or Former Address, if Changed Since Last Report)</p><div style="font-family:'Times New Roman';font-size:13.5pt;margin-bottom:6pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:38.36%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Check the appropriate box below if the Form&#160;8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction&#160;A.2. below):</p><a id="_e66d1806_114f_4f24_b753_e9c0be25034d"></a><a id="Tc_CAHflZbIfU2yYvoZRpeFXg_2_1"></a><a id="Tc_TQMRf6VbxUC6glFYJn7vVg_4_1"></a><a id="Tc_3iQ5-nf4bUeo52FAtjyucg_6_1"></a><a id="Tc__w9BbPF-6UuE0_eMU64y-g_8_1"></a><table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:4%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:96%;margin:0pt;padding:0pt;"></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_5_15_2020_To_5_15_2020_JKlsoBudLEG9zjmLPSA4Ow" format="ixt-sec:boolballotbox" name="dei:WrittenCommunications" id="Tc_aWuDZkUNDkyYwCEexiQ8Xg_2_0"><span style="font-family:'Segoe UI Symbol';font-size:10pt;">&#9744;</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Written communications pursuant to Rule&#160;425 under the Securities Act (17&#160;CFR&#160;230.425)</p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_5_15_2020_To_5_15_2020_JKlsoBudLEG9zjmLPSA4Ow" format="ixt-sec:boolballotbox" name="dei:SolicitingMaterial" id="Tc_Ik-QeWLybEKKwJwqGO4ERA_4_0"><span style="font-family:'Segoe UI Symbol';font-size:10pt;">&#9744;</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Soliciting material pursuant to Rule&#160;14a-12 under the Exchange Act (17&#160;CFR&#160;240.14a-12)</p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_5_15_2020_To_5_15_2020_JKlsoBudLEG9zjmLPSA4Ow" format="ixt-sec:boolballotbox" name="dei:PreCommencementTenderOffer" id="Tc_bKU1q5KtDE-G_MQbtzWmVQ_6_0"><span style="font-family:'Segoe UI Symbol';font-size:10pt;">&#9744;</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Pre-commencement communications pursuant to Rule&#160;14d-2(b) under the Exchange Act (17&#160;CFR&#160;240.14d-2(b))</p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_5_15_2020_To_5_15_2020_JKlsoBudLEG9zjmLPSA4Ow" format="ixt-sec:boolballotbox" name="dei:PreCommencementIssuerTenderOffer" id="Tc_5PKFB8PcsU2pzAqpk06jmg_8_0"><span style="font-family:'Segoe UI Symbol';font-size:10pt;">&#9744;</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Pre-commencement communications pursuant to Rule&#160;13e-4(c) under the Exchange Act (17&#160;CFR&#160;240.13e-4(c))</p></td></tr></table><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt 0pt 12pt 0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 6pt 0pt;">Securities registered pursuant to Section 12(b) of the Act:</p><a id="_dcb8c928_e46c_434f_a26a_0d9cf6b41806"></a><a id="Tc_V_ylUWRXEkyQ_d3Piq2Hag_1_0"></a><a id="Tc_biJibd3FFEGIdn-X1vKMTg_1_1"></a><a id="Tc_8-ElDzyFrUODYxlhhXx30w_1_2"></a><table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:33.33%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:33.34%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:33.32%;margin:0pt;padding:0pt;"></td></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:33.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;padding-left:10pt;text-align:center;text-indent:-10pt;margin:0pt;"><b style="font-weight:bold;">Title of each class</b></p></td><td style="vertical-align:bottom;width:33.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Trading Symbol(s)</b></p></td><td style="vertical-align:bottom;width:33.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Name of each exchange on which registered</b></p></td></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:33.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;padding-left:10pt;text-align:center;text-indent:-10pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_5_15_2020_To_5_15_2020_JKlsoBudLEG9zjmLPSA4Ow" name="dei:Security12bTitle" id="Tc_S0jQ6-83P0WJmCpKvECv9A_2_0"><span style="font-size:8pt;">Common Stock, $0.0001 par value per share</span></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:33.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_5_15_2020_To_5_15_2020_JKlsoBudLEG9zjmLPSA4Ow" name="dei:TradingSymbol" id="Tc_q_3HHMfKW0ibolWfh_K7qQ_2_1"><span style="font-size:8pt;">EDIT</span></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:33.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_5_15_2020_To_5_15_2020_JKlsoBudLEG9zjmLPSA4Ow" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="Tc_yvfb8Cmgm02dPMt_xT_QIw_2_2"><span style="font-size:8pt;">The Nasdaq Stock Market LLC</span></ix:nonNumeric></p></td></tr></table><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 6pt 0pt;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule&#160;405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule&#160;12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-<span style="white-space:pre-wrap;">2 of this chapter).    </span></p><p style="font-family:'Times New Roman';font-size:12pt;text-indent:36pt;margin:6pt 0pt 6pt 0pt;"><span style="font-size:10pt;">Emerging growth company&#160;</span><ix:nonNumeric contextRef="Duration_5_15_2020_To_5_15_2020_JKlsoBudLEG9zjmLPSA4Ow" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="Narr_iwvi-4VRGkyGYZ-MWa07gg"><span style="font-family:'Segoe UI Symbol';font-size:10pt;">&#9744;</span></ix:nonNumeric></p><p style="font-family:'Times New Roman';font-size:10pt;margin:6pt 0pt 6pt 0pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a)&#160;of the Exchange Act.&#160;<span style="font-family:'Segoe UI Symbol';">&#9744;</span>&#160;</p><p style="font-family:'Times New Roman';font-size:3pt;padding-bottom:1pt;padding-top:1pt;border-bottom:3.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman';font-size:3pt;margin:0pt;">&#160;</p><p style="display:none;font-size:12pt;line-height:0pt;margin:0pt 0pt 12pt 0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:0pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><a id="_38fec2ac_ecf0_4ca2_876d_e68f20111f99"></a></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><a id="_Hlk535744647"></a><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item&#160;</b><b style="font-weight:bold;">1.01.</b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b style="font-weight:bold;">Entry into a Material Definitive Agreement.</b></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On May 15, 2020, Editas Medicine, Inc. (the &quot;Company&quot;) entered into a Common Stock Sales Agreement (the &quot;Sales Agreement&quot;) with Cowen and Company, LLC, as agent (&quot;Cowen&quot;), pursuant to which the Company may issue and sell shares of its common stock, $0.0001 par value per share, having an aggregate offering price of up to $150,000,000 (the &quot;Shares&quot;), from time to time through Cowen (the &quot;Offering&quot;). Also, on May 15, 2020, the Company is filing a prospectus supplement with the Securities and Exchange Commission in connection with the Offering (the &quot;Prospectus Supplement&quot;) under its existing automatic shelf registration statement, which became effective on March 12, 2018 (File No. 333-223596), and the base prospectus contained therein.</p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Upon delivery of a placement notice, and subject to the terms and conditions of the Sales Agreement, Cowen may sell the Shares by methods deemed to be an &quot;at the market offering&quot; as defined in Rule 415(a)(4) promulgated under the Securities Act of 1933, as amended. The Company may sell the Shares in amounts and at times to be determined by the Company from time to time subject to the terms and conditions of the Sales Agreement, but it has no obligation to sell any of the Shares in the Offering.</p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company or Cowen may suspend or terminate the Offering upon notice to the other party and subject to other conditions. Cowen will act as sales agent on a commercially reasonable efforts basis consistent with its normal trading and sales practices and applicable state and federal law, rules and regulations and the rules of The Nasdaq Global Select Market.</p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company has agreed to pay Cowen commissions for its services in acting as agent in the sale of the Shares in the amount of up to 3.0% of gross proceeds from the sale of the Shares pursuant to the Sales Agreement. The Company has also agreed to provide Cowen with customary indemnification and contribution rights.</p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">A copy of the Sales Agreement is attached as Exhibit 1.1 hereto and is incorporated herein by reference. The foregoing description of the material terms of the Sales Agreement does not purport to be complete and is qualified in its entirety by reference to such exhibit.</p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Wilmer Cutler Pickering Hale and Dorr LLP, counsel to the Company, has issued a legal opinion relating to the Shares. A copy of such legal opinion, including the consent included therein, is attached as Exhibit 5.1 hereto.</p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Shares are registered pursuant to an effective shelf Registration Statement on Form S-3 (File No. 333-223596) and the base prospectus contained therein, and offerings for the Shares will be made only by means of the Prospectus Supplement. This Current Report on Form 8-K shall not constitute an offer to sell or solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities law of such state or jurisdiction.</p><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item&#160;9.01.</b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b style="font-weight:bold;">Financial Statements and Exhibits.</b></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:19.45pt;margin:0pt 0pt 12pt 0pt;">(d)&#160;Exhibits</p><table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:6.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:91.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:6.77%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Exhibit<br />No.</b></p></td><td style="vertical-align:bottom;width:2.08%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:91.14%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Description</b></p></td></tr><tr><td style="vertical-align:top;width:6.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;">1.1</p></td><td style="vertical-align:bottom;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:91.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><a href="edit-20200515xex1d1.htm"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Common Stock Sales Agreement, dated as of May 15, 2020, by and between the Company and Cowen</span></a> </p></td></tr><tr><td style="vertical-align:bottom;width:6.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;">5.1</p></td><td style="vertical-align:bottom;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:91.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><a href="edit-20200515xex5d1.htm"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Opinion of Wilmer Cutler Pickering Hale and Dorr LLP</span></a></p></td></tr><tr><td style="vertical-align:bottom;width:6.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;">23.1</p></td><td style="vertical-align:bottom;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:91.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><a href="edit-20200515xex5d1.htm"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Consent of Wilmer Cutler Pickering Hale and Dorr LLP (included in Exhibit 5.1)</span></a></p></td></tr><tr><td style="vertical-align:bottom;width:6.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt;">104</p></td><td style="vertical-align:bottom;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:91.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">The cover page from this Current Report on Form 8-K, formatted in Inline XBRL</p></td></tr></table><p style="background-color:#ffffff;font-family:'Times New Roman';font-size:12pt;margin:14pt 0pt 0pt 0pt;"><span style="font-size:1pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:12pt;margin:14pt 0pt 12pt 0pt;"><span style="font-size:13.5pt;visibility:hidden;">&#8203;</span></p><a id="_8f9f64c6_d44b_4448_bd59_c00f07621b52"></a></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:76.47%;border:0;margin:30pt 11.76% 30pt 11.76%;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">SIGNATURES</p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p><table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:47.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">EDITAS MEDICINE, INC.</p></td></tr><tr style="height:1pt;"><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:47.98%;margin:0pt;padding:0pt;"></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Date:</p></td><td style="vertical-align:top;width:45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">May 15, 2020</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:top;width:43.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">/s/ Michelle Robertson</p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:10pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.99%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:43.99%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;">Michelle Robertson <br />Chief Financial Officer</p></td></tr></table><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:12pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:avoid;width:76.47%;border:0;"></div></body></html>
[{"type": "8-K", "sequence": "1", "filename": "edit-20200515x8k.htm", "description": "8-K", "secsgml_size_bytes": 38455}]
{"company-data": {"conformed-name": "Editas Medicine, Inc.", "cik": "0001650664", "assigned-sic": "2836", "irs-number": "464097528", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "001-37687", "film-number": "20884960"}, "business-address": {"street1": "11 HURLEY ST.", "city": "CAMBRIDGE", "state": "MA", "zip": "02141", "phone": "617-401-9000"}, "mail-address": {"street1": "11 HURLEY ST.", "city": "CAMBRIDGE", "state": "MA", "zip": "02141"}}
​
​
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
May 15, 2020
Editas Medicine, Inc.
(Exact Name of Registrant as Specified in its Charter)
​
​
Delaware
​
001-37687
​
46-4097528
(State or Other Jurisdiction of Incorporation)
​
(Commission File Number)
​
(IRS Employer Identification No.)
​
​
11 Hurley Street
Cambridge
,
Massachusetts
​
02141
(Address of Principal Executive Offices)
​
(Zip Code)
​
Registrant's telephone number, including area code:
(
617
)
401-9000
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
​
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, $0.0001 par value per share
EDIT
The Nasdaq Stock Market LLC
​
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-
2 of this chapter).
Emerging growth company
☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
☐
Item
1.01.
Entry into a Material Definitive Agreement.
On May 15, 2020, Editas Medicine, Inc. (the "Company") entered into a Common Stock Sales Agreement (the "Sales Agreement") with Cowen and Company, LLC, as agent ("Cowen"), pursuant to which the Company may issue and sell shares of its common stock, $0.0001 par value per share, having an aggregate offering price of up to $150,000,000 (the "Shares"), from time to time through Cowen (the "Offering"). Also, on May 15, 2020, the Company is filing a prospectus supplement with the Securities and Exchange Commission in connection with the Offering (the "Prospectus Supplement") under its existing automatic shelf registration statement, which became effective on March 12, 2018 (File No. 333-223596), and the base prospectus contained therein.
Upon delivery of a placement notice, and subject to the terms and conditions of the Sales Agreement, Cowen may sell the Shares by methods deemed to be an "at the market offering" as defined in Rule 415(a)(4) promulgated under the Securities Act of 1933, as amended. The Company may sell the Shares in amounts and at times to be determined by the Company from time to time subject to the terms and conditions of the Sales Agreement, but it has no obligation to sell any of the Shares in the Offering.
The Company or Cowen may suspend or terminate the Offering upon notice to the other party and subject to other conditions. Cowen will act as sales agent on a commercially reasonable efforts basis consistent with its normal trading and sales practices and applicable state and federal law, rules and regulations and the rules of The Nasdaq Global Select Market.
The Company has agreed to pay Cowen commissions for its services in acting as agent in the sale of the Shares in the amount of up to 3.0% of gross proceeds from the sale of the Shares pursuant to the Sales Agreement. The Company has also agreed to provide Cowen with customary indemnification and contribution rights.
A copy of the Sales Agreement is attached as Exhibit 1.1 hereto and is incorporated herein by reference. The foregoing description of the material terms of the Sales Agreement does not purport to be complete and is qualified in its entirety by reference to such exhibit.
Wilmer Cutler Pickering Hale and Dorr LLP, counsel to the Company, has issued a legal opinion relating to the Shares. A copy of such legal opinion, including the consent included therein, is attached as Exhibit 5.1 hereto.
The Shares are registered pursuant to an effective shelf Registration Statement on Form S-3 (File No. 333-223596) and the base prospectus contained therein, and offerings for the Shares will be made only by means of the Prospectus Supplement. This Current Report on Form 8-K shall not constitute an offer to sell or solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities law of such state or jurisdiction.
Item 9.01.
Financial Statements and Exhibits.
(d) Exhibits
Exhibit
No.
Description
1.1
Common Stock Sales Agreement, dated as of May 15, 2020, by and between the Company and Cowen
5.1
Opinion of Wilmer Cutler Pickering Hale and Dorr LLP
23.1
Consent of Wilmer Cutler Pickering Hale and Dorr LLP (included in Exhibit 5.1)
104
​
The cover page from this Current Report on Form 8-K, formatted in Inline XBRL
​
​
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
​
EDITAS MEDICINE, INC.
​
Date:
May 15, 2020
​
By:
/s/ Michelle Robertson
​
​
​
Michelle Robertson
Chief Financial Officer
​
​
​